Cargando…
Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report
The anti-CV2/CRMP5 antibody is a well-characterized biomarker of paraneoplastic neurological syndrome. The anti-NF186 antibody is a recently discovered antibody associated with central or peripheral demyelination. The co-occurrence of these two antibodies has not been reported. Herein, we report a c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046875/ https://www.ncbi.nlm.nih.gov/pubmed/36979184 http://dx.doi.org/10.3390/brainsci13030374 |
_version_ | 1785013781821128704 |
---|---|
author | Liu, Bingyou Zhou, Lei Zheng, Yongsheng Sun, Chong Lin, Jie |
author_facet | Liu, Bingyou Zhou, Lei Zheng, Yongsheng Sun, Chong Lin, Jie |
author_sort | Liu, Bingyou |
collection | PubMed |
description | The anti-CV2/CRMP5 antibody is a well-characterized biomarker of paraneoplastic neurological syndrome. The anti-NF186 antibody is a recently discovered antibody associated with central or peripheral demyelination. The co-occurrence of these two antibodies has not been reported. Herein, we report a case with anti-CV2/CRMP5 and anti-NF186 antibodies in a 57-year-old male presenting with progressive numbness and weakness in his four limbs. At first admission, the spinal cord MRI showed a cervical cord demyelinating lesion and electrophysiological examination showed a mixed demyelinating and axonal polyneuropathy. Anti-CV2/CRMP5 and anti-NF186 antibodies were both detected in his serum. Initially, the patient showed a positive response to IVIG and glucocorticoid treatment. However, the syndrome relapsed and mass lesions in lung and mediastinum were detected at second admission. This time the anti-NF186 antibody was not detected but the anti-CV2/CRMP5 antibody was still present. IVIG and glucocorticoid treatment was no longer effective. This case illustrated that paraneoplastic syndrome should be considered when diagnosing patients with central and peripheral demyelination, and that the anti-NF186 antibody may help distinguish a subset of patients who can benefit from immunomodulatory treatments. |
format | Online Article Text |
id | pubmed-10046875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100468752023-03-29 Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report Liu, Bingyou Zhou, Lei Zheng, Yongsheng Sun, Chong Lin, Jie Brain Sci Case Report The anti-CV2/CRMP5 antibody is a well-characterized biomarker of paraneoplastic neurological syndrome. The anti-NF186 antibody is a recently discovered antibody associated with central or peripheral demyelination. The co-occurrence of these two antibodies has not been reported. Herein, we report a case with anti-CV2/CRMP5 and anti-NF186 antibodies in a 57-year-old male presenting with progressive numbness and weakness in his four limbs. At first admission, the spinal cord MRI showed a cervical cord demyelinating lesion and electrophysiological examination showed a mixed demyelinating and axonal polyneuropathy. Anti-CV2/CRMP5 and anti-NF186 antibodies were both detected in his serum. Initially, the patient showed a positive response to IVIG and glucocorticoid treatment. However, the syndrome relapsed and mass lesions in lung and mediastinum were detected at second admission. This time the anti-NF186 antibody was not detected but the anti-CV2/CRMP5 antibody was still present. IVIG and glucocorticoid treatment was no longer effective. This case illustrated that paraneoplastic syndrome should be considered when diagnosing patients with central and peripheral demyelination, and that the anti-NF186 antibody may help distinguish a subset of patients who can benefit from immunomodulatory treatments. MDPI 2023-02-21 /pmc/articles/PMC10046875/ /pubmed/36979184 http://dx.doi.org/10.3390/brainsci13030374 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Liu, Bingyou Zhou, Lei Zheng, Yongsheng Sun, Chong Lin, Jie Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report |
title | Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report |
title_full | Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report |
title_fullStr | Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report |
title_full_unstemmed | Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report |
title_short | Paraneoplastic Syndrome Presenting Combined Central and Peripheral Demyelination Associated with Anti-CV2/CRMP5 and Anti-NF186 Antibodies: A Case Report |
title_sort | paraneoplastic syndrome presenting combined central and peripheral demyelination associated with anti-cv2/crmp5 and anti-nf186 antibodies: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046875/ https://www.ncbi.nlm.nih.gov/pubmed/36979184 http://dx.doi.org/10.3390/brainsci13030374 |
work_keys_str_mv | AT liubingyou paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport AT zhoulei paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport AT zhengyongsheng paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport AT sunchong paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport AT linjie paraneoplasticsyndromepresentingcombinedcentralandperipheraldemyelinationassociatedwithanticv2crmp5andantinf186antibodiesacasereport |